Based on RASi clinical data, three Phase II trial designs are proposed to validate the efficacy of polyphenols in cancer treatment: (1) The first trial targets metastatic CRC, building on the synergy between losartan and vitamin D. This trial would enroll 150 patients stratified by AT1R expression. Here, AGTR1 is linked to colorectal carcinoma.